[Form 4] Acuren Corporation Insider Trading Activity

Rhea-AI Filing Summary

Kristin B. Schultes, Chief Financial Officer of Acuren Corporation (TIC), received equity awards and reports her beneficial ownership. The Form 4 shows a reported acquisition on 08/21/2025 of 60,000 performance-based restricted stock units (PSUs) with an exercise/price reported as $0, indicating they were granted rather than purchased. The filing also lists existing awards: three tranches of restricted stock units of 30,000 each and other performance-based RSUs totaling 150,000 across multiple grants and vesting schedules. Some grants vest on anniversaries (e.g., December 3, 2024 grant vests one-third per year) and others vest subject to stock price performance or multi-year performance periods (vesting dates include 12/03/2025, 04/11/2028, and 09/30/2026 as applicable). The form was signed by an attorney-in-fact on 08/25/2025.

Positive

• Long-term alignment: Awards include performance-based RSUs that tie executive compensation to future stock performance and multi-year vesting.
• Retention-focused structure: Multiple grants with staggered vesting dates support executive retention over several years.

Negative

• None.

Insights

Financial Analyst

TL;DR: CFO received a material equity incentive package, aligning compensation with long-term share performance.

The 60,000 PSUs reported on 08/21/2025 are standard executive compensation designed to align management incentives with shareholder value. The grant is reported at $0 price, consistent with restricted stock unit awards rather than an open-market purchase. Multiple awards and staggered vesting schedules (time-based and performance-based) spread potential dilution over several years and tie ultimate payout to performance hurdles and service periods. This structure typically supports retention and long-term focus without immediate cash outlay by the officer.

Corporate Governance Expert

TL;DR: Governance appears routine: time- and performance-based RSUs with standard vesting and performance conditions.

The filing documents a mixture of time-vested RSUs and performance-vested RSUs with explicit vesting triggers and dates. The PSUs that vest based on a specified VWAP metric and multi-year performance periods reflect common governance practices to link pay to sustained stock performance. The disclosure includes vesting timelines and contingencies, providing transparency on potential future share issuance subject to achievement of performance targets and service requirements.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

SCHULTES KRISTIN B

(Last) (First) (Middle)

C/O ACUREN CORPORATION

14434 MEDICAL COMPLEX DRIVE, SUITE 100

(Street)

TOMBALL TX 77377

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ACUREN CORP [ TIC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF FINANCIAL OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
08/21/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)							(2)	(2)	Common Stock	30,000		30,000	D
Performance Based Restricted Stock Units	(3)							(4)	12/03/2029	Common Stock	30,000		30,000	D
Restricted Stock Units	(1)							(5)	(5)	Common Stock	30,000		30,000	D
Performance Based Restricted Stock Units	(3)							(6)	(6)	Common Stock	60,000		60,000	D
Performance Based Restricted Stock Units	(3)	08/21/2025		A		60,000		(7)	(7)	Common Stock	60,000	$0	60,000	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock.

2. These restricted stock units vest 33 1/3% on the first through third anniversaries of the grant date (December 3, 2024).

3. Each performance based restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock.

4. These performance based restricted stock units shall vest, beginning on December 3, 2025, based on the Issuer's Common Stock achieving a specified volume-weighted average price per share over a 10-day period.

5. These restricted stock units vest on the third anniversary of the grant date (April 11, 2025).

6. These performance based restricted stock units have a three-year performance period and to the extent earned will vest on April 11, 2028. The number of shares of Common Stock that will be earned is subject to decrease based on the result of the performance condition.

7. These performance based restricted stock units, to the extent earned, will vest on September 30, 2026. The number of shares of Common Stock that will be earned is subject to decrease based on the results of the performance condition.

Remarks:

Exhibit 24.1 - Power of Attorney

	/s/ MaryJo O'Brien, Attorney in Fact	08/25/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Acuren CFO Kristin Schultes acquire on 08/21/2025?

The filing reports an acquisition of 60,000 performance-based restricted stock units on 08/21/2025.

Are the reported awards time-based or performance-based?

The filing lists both: time-based restricted stock units (vesting on anniversaries) and performance-based restricted stock units that vest based on stock-price or other performance conditions.

What are the key vesting dates mentioned in the Form 4?

Noted vesting dates include 12/03/2025 (performance vesting begins), 04/11/2028 (time- and performance-based awards may vest), and 09/30/2026 for certain PSUs, plus annual anniversaries from grant dates.

What does the $0 price on the 60,000 PSUs mean?

The filing shows a price of $0, indicating these were granted as restricted stock units rather than purchased shares.

Who signed the Form 4 filing for Kristin Schultes?

The Form 4 was signed by MaryJo O'Brien, Attorney in Fact on 08/25/2025.